1995 **AACR Launches First Clinical** Journal: Clinical Cancer Research



Inaugural Editorial

1996

2003

MIMMIMMM

Clinical Cancer

First Table of Contents

JOHN MENDELSOHN, MD, FOUNDING EDITOR-IN-CHIEF, 1995-2004

Internationally recognized for demonstrating how the binding of growth

Zayed Al Nahyan Institute for Personalized Cancer Therapy.

factors to cell surface receptors regulates cell function, Dr. Mendelsohn, with his collaborators at the University of California, San Diego, produced monoclonal antibody 225, which inhibits cancer cell proliferation by blocking activation of the tyrosine kinase function of the epidermal growth factor receptor. His subsequent research in both the laboratory and the clinic pioneered the universally adopted concept of anti-receptor and anti-tyrosine kinase therapy that targets key cell signaling pathways as a new form of cancer treatment. Dr. Mendelsohn oversaw a period of substantial growth as President of the University of Texas MD Anderson Cancer Center and now serves as Director of the Sheikh Khalifa Bin

Inaugural Editorial

First Impact Factor: 3.162

Identifying the Biologically Active Dose of Sunitinib in Clinical Trials

HIGHLY CITED ARTICLE

In Viro Antitumor Activity of SU11248, a Novel Tyrosine Kin Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship

<text><text><section-header><section-header><text><text><text>

Barrard 4702, annual 12020, appanel 12020, appan



SU11248 ×

FIGURE 3. SU11248 treatment results in inhibition of SF763T tumor MVD. Mice bearing established (500 mm3) SF763T tumors were treated with SU11248 at 80 mg/kg/day or with vehicle. Tumors were harvested 13 days after initiation or freatment (9 days in the case of vehicle because of rapid tumor growth). Tumors were fixed, paraffin-embedded, sectioned, immunostained for CD31, and counterstained with hematoxylin. Representative X400 fields are shown Arrows indicate CD31-positive cells (vessel elements).

2004 Journal Begins Twice Monthly Publication

CCR's Top-Cited Article

HIGHLY CITED ARTICLE

Featured Article

Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

Note that the second s

APCOMUME Fronts: Using a gener approximate profiles, we can be the distribution of the product of the product of the the observation of the product of the product of the best observation, HERM, and the ZAIC. Toget protocols for bandle based approximation of the ZAIC is clear protocols of the based approximation of the ZAIC. Toget protocols for the based approximation of the ZAIC is clear protocols of the based approximation of the ZAIC is clear protocols with the discovery derived and constrained with pro-tice of the ZAIC is clear protocols of the the ZAIC is clear protocols with the discovery derived and constrained with pro-tice of the ZAIC is clear protocols. The ZAIC is clear protocols with the discovery derived and constrained with pro-tice of the ZAIC is clear protocols. The ZAIC is clear and the interval of the ZAIC is clear and the low protocols of the based on the protocols. The ZAIC is clear and the low derived the protocols and the clear derived and the discovery pro-tice of the ZAIC is clear and the low derived by the mean energy and the relation derived by the low derived the protocols. The discovery and the low derived by the mean energy and the relation derived by the discovery and the protocols. The discovery and the low derived by the low derived the low derived approximation of the LAIC is and the low derived by the mean energy and the relation derived by the low derived by the low derived approximation of the low derived by the low derived by the low derived approximation of the low derived by the low derived by the low derived approximation of the low derived by the low derived by the low derived approximation of the low derived by the low derived by the low derived approximation of the low derived by the low derived

<text><text><text><text><footnote><footnote><footnote><footnote><footnote>



correlation with immunohistochemistry. A, the 115 patient/tumor sample dendrogram was taken from the hierarchical clustering analysis presented in Sortie et al. (2); the tumors were grouped using the breast intrinsic gene list based on 45 paired samples. Using the breast infinition gene his based on 49 panets an hipes. The basal-like breast cancers are identified in red. The gene expression data for ER, HER2, c-KIT, cytokeratin (CK)5, and HER1 are shown with red squares representing the highest average expression, black representing average gene expression, and green representing the lowest below average. B, 21 basal-like breast cancers infinited by mere average to prefilion over to trad and scored by IHC for CK5/6, HERI, c-K1T, ER, and HER2 (0 = negative, 1 = weak and/or focal staining, 2 = strong diffuse staining), except for HER2, which was scored using a standard (0-3+) scale. ND = not determined (- representative interpretative for the factors) determined. C, representative immunostaining results for four basa like tumors and a normal breast sample for CK5/6 and HER1

FIGURE 1. Gene expression patterns in basal-like tumors and their

SCIENTIFIC PUBLISHING CENTENNIAL



American Association for Cancer Research

2004 Reliable Tool Found to Investigate Circulating Tumor Cells in Clinical Utility

HIGHLY CITED ARTICLE

fumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With imalignant Diseases

Boologine Valles, Passeptivales and sease and Department of Misselforage manter Maduat Classes & Dalas,

andorsite pro-per 1.5 mil cascas, 40 c (Ni of 2.365) of the spacings of 2.65 of the bill of Table constraint at the bill 27% (200

control worked works, accepted Tokks, al patholines was achieved in part is part patholines. Since and works and an part is part patholines. Since and works and an acception of an patholines with a CALC. Assess Christer and a patholines with a CALC. Assess Christer and a patholines and a CALC. Assess Christer and a MATERIALS AND MR mathyline and acception of a patholine and analysis of a CALC.



FIGURE 4. Gallery of CTC images from the CellSpotter Analyze obtained from 7.5 mL of blood from cancer patients. A shows examples of typical intact CTCs, B shows examples of intact CTCs present as clusters or with odd shapes that are present less frequently, and C provides examples of CTC fragments and apoptotic CTCs. Images presented in C were not included in the CTC counts but are frequently observed in CTC analysis of na patients



Institute Director Named Editor-in-Chief



WILLIAM N. HAIT, MD, PHD, EDITOR-IN-CHIEF, 2005-2007





KENNETH C. ANDERSON, MD, EDITOR-IN-CHIEF, 2007-PRESENT

2014 **Impact Factor Reaches Record** High of 8.722



American Association for Cancer Research